Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 30 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

57%

13 of 23 completed trials have results

Key Signals

4 recruiting13 with results

Enrollment Performance

Analytics

N/A
24(96.0%)
Phase 3
1(4.0%)
25Total
N/A(24)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials
NCT07317102Recruiting

Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

Role: lead

NCT07276776Not ApplicableCompleted

An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

Role: lead

NCT07039942Recruiting

French Prospective Multicentric Study in Real World

Role: lead

NCT06144554Recruiting

Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

Role: lead

NCT07521475Not ApplicableNot Yet Recruiting

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

Role: lead

NCT05923827Not ApplicableCompleted

Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

Role: lead

NCT07423637Not ApplicableNot Yet Recruiting

The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment

Role: collaborator

NCT07039981Not ApplicableActive Not Recruiting

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes

Role: lead

NCT07070830Not ApplicableCompleted

Simplified Onboarding in Adults With Type 2 Diabetes

Role: lead

NCT06547918Not ApplicableCompleted

SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes

Role: lead

NCT06865989Not ApplicableCompleted

Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

Role: lead

NCT05815342Not ApplicableCompleted

OP5-005 Using Omnipod 5 in Adults With Type 2

Role: lead

NCT05409131Not ApplicableCompleted

Omnipod 5 System Compared to Pump Therapy

Role: lead

NCT04617795Not ApplicableCompleted

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

Role: lead

NCT04196140Not ApplicableCompleted

Pivotal Omnipod Horizon™ Automated Glucose Control System

Role: lead

NCT04714216Not ApplicableCompleted

Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility

Role: collaborator

NCT06181721Not ApplicableCompleted

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes

Role: lead

NCT04476472Not ApplicableCompleted

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

Role: lead

NCT04320069Not ApplicableCompleted

Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study

Role: lead

NCT04176731Not ApplicableCompleted

Prepivotal Omnipod Horizon™ Automated Glucose Control System

Role: lead